BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Rodríguez-Núñez O, Periañez-Parraga L, Oliver A, Munita JM, Boté A, Gasch O, Nuvials X, Dinh A, Shaw R, Lomas JM, Torres V, Castón J, Araos R, Abbo LM, Rakita R, Pérez F, Aitken SL, Arias CA, Martín-Pena ML, Colomar A, Núñez MB, Mensa J, Martínez JA, Soriano A. Higher MICs (>2 mg/L) Predict 30-Day Mortality in Patients With Lower Respiratory Tract Infections Caused by Multidrug- and Extensively Drug-Resistant Pseudomonas aeruginosa Treated With Ceftolozane/Tazobactam. Open Forum Infect Dis 2019;6:ofz416. [PMID: 31660373 DOI: 10.1093/ofid/ofz416] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Los-Arcos I, Burgos J, Falcó V, Almirante B. An overview of ceftolozane sulfate + tazobactam for treating hospital acquired pneumonia. Expert Opin Pharmacother 2020;21:1005-13. [PMID: 32212866 DOI: 10.1080/14656566.2020.1739269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Nasomsong W, Nulsopapon P, Changpradub D, Pungcharoenkijkul S, Hanyanunt P, Chatreewattanakul T, Santimaleeworagun W. Optimizing Doses of Ceftolozane/Tazobactam as Monotherapy or in Combination with Amikacin to Treat Carbapenem-Resistant Pseudomonas aeruginosa. Antibiotics 2022;11:517. [DOI: 10.3390/antibiotics11040517] [Reference Citation Analysis]
3 Ronda M, Pérez-Recio S, González Laguna M, Tubau Quintano MF, Llop Talaveron J, Soldevila-Boixader L, Carratalà J, Cuervo G, Padullés A. Ceftolozane/tazobactam for difficult-to-treat Gram-negative infections: A real-world tertiary hospital experience. J Clin Pharm Ther 2022. [PMID: 35255527 DOI: 10.1111/jcpt.13623] [Reference Citation Analysis]
4 Gatti M, Viaggi B, Rossolini GM, Pea F, Viale P. An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients. Antibiotics (Basel) 2021;11:33. [PMID: 35052910 DOI: 10.3390/antibiotics11010033] [Reference Citation Analysis]
5 Kunz Coyne AJ, El Ghali A, Holger D, Rebold N, Rybak MJ. Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa. Infect Dis Ther 2022. [PMID: 35150435 DOI: 10.1007/s40121-022-00591-2] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
6 Fiore M, Corrente A, Pace MC, Alfieri A, Simeon V, Ippolito M, Giarratano A, Cortegiani A. Ceftolozane-Tazobactam Combination Therapy Compared to Ceftolozane-Tazobactam Monotherapy for the Treatment of Severe Infections: A Systematic Review and Meta-Analysis. Antibiotics (Basel) 2021;10:79. [PMID: 33467508 DOI: 10.3390/antibiotics10010079] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
7 Luyt CE, Bouadma L, Morris AC, Dhanani JA, Kollef M, Lipman J, Martin-Loeches I, Nseir S, Ranzani OT, Roquilly A, Schmidt M, Torres A, Timsit JF. Pulmonary infections complicating ARDS. Intensive Care Med 2020;46:2168-83. [PMID: 33175277 DOI: 10.1007/s00134-020-06292-z] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
8 Valero A, Rodríguez-Gascón A, Isla A, Barrasa H, Del Barrio-Tofiño E, Oliver A, Canut A, Solinís MÁ. Pseudomonas aeruginosa Susceptibility in Spain: Antimicrobial Activity and Resistance Suppression Evaluation by PK/PD Analysis. Pharmaceutics 2021;13:1899. [PMID: 34834314 DOI: 10.3390/pharmaceutics13111899] [Reference Citation Analysis]
9 Perez LRR, Carniel E, Narvaez GA. High minimum inhibitory concentrations among derepressed AmpC-beta-lactamase–producing Enterobacter cloacae complex isolates for ceftolozane with tazobactam. Infect Control Hosp Epidemiol 2020;41:631-3. [DOI: 10.1017/ice.2020.31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
10 Bassetti M, Russo C, Vena A, Giacobbe DR. New antibiotics for the treatment of nonfermenting Gram-negative bacteria. Curr Opin Infect Dis 2021;34:701-9. [PMID: 34637210 DOI: 10.1097/QCO.0000000000000757] [Reference Citation Analysis]
11 Montero MM, Domene-Ochoa S, López-Causapé C, Luque S, Sorlí L, Campillo N, Padilla E, Prim N, Ferrer-Alapont L, Angulo-Brunet A, Grau S, Oliver A, Horcajada JP. Impact of ceftolozane/tazobactam concentrations in continuous infusion against extensively drug-resistant Pseudomonas aeruginosa isolates in a hollow-fiber infection model. Sci Rep 2021;11:22178. [PMID: 34773066 DOI: 10.1038/s41598-021-01784-4] [Reference Citation Analysis]
12 Puzniak L, Dillon R, Palmer T, Collings H, Enstone A. Systematic Literature Review of Real-world Evidence of Ceftolozane/Tazobactam for the Treatment of Respiratory Infections. Infect Dis Ther 2021;10:1227-52. [PMID: 34278551 DOI: 10.1007/s40121-021-00491-x] [Reference Citation Analysis]
13 Zhanel GG, Dhami R, Baxter M, Kosar J, Cervera C, Irfan N, Zvonar R, Borgia S, Tessier JF, Dow G, Ariano R, Dube M, Savoie M, Bassetti M, Walkty A, Karlowsky JA. Real-life experience with ceftolozane/tazobactam in Canada: results from the CLEAR (Canadian LEadership on Antimicrobial Real-life usage) registry. J Glob Antimicrob Resist 2021;25:346-50. [PMID: 33984530 DOI: 10.1016/j.jgar.2021.03.025] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Puzniak L, Dillon R, Palmer T, Collings H, Enstone A. Real-world use of ceftolozane/tazobactam: a systematic literature review. Antimicrob Resist Infect Control 2021;10:68. [PMID: 33832545 DOI: 10.1186/s13756-021-00933-8] [Reference Citation Analysis]
15 Garazzino S, Altieri E, Silvestro E, Pruccoli G, Scolfaro C, Bignamini E. Ceftolozane/Tazobactam for Treating Children With Exacerbations of Cystic Fibrosis Due to Pseudomonas aeruginosa: A Review of Available Data. Front Pediatr 2020;8:173. [PMID: 32432060 DOI: 10.3389/fped.2020.00173] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Lizza BD, Betthauser KD, Ritchie DJ, Micek ST, Kollef MH. New Perspectives on Antimicrobial Agents: Ceftolozane-Tazobactam. Antimicrob Agents Chemother 2021;65:e0231820. [PMID: 33875428 DOI: 10.1128/AAC.02318-20] [Reference Citation Analysis]